337 related articles for article (PubMed ID: 22210744)
1. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor.
Davey AE; Leach K; Valant C; Conigrave AD; Sexton PM; Christopoulos A
Endocrinology; 2012 Mar; 153(3):1232-41. PubMed ID: 22210744
[TBL] [Abstract][Full Text] [Related]
2. Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics.
Cook AE; Mistry SN; Gregory KJ; Furness SG; Sexton PM; Scammells PJ; Conigrave AD; Christopoulos A; Leach K
Br J Pharmacol; 2015 Jan; 172(1):185-200. PubMed ID: 25220431
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators.
Leach K; Wen A; Cook AE; Sexton PM; Conigrave AD; Christopoulos A
Endocrinology; 2013 Mar; 154(3):1105-16. PubMed ID: 23372019
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
5. Calcium-sensing receptor-dependent activation of CREB phosphorylation in HEK293 cells and human parathyroid cells.
Avlani VA; Ma W; Mun HC; Leach K; Delbridge L; Christopoulos A; Conigrave AD
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1097-104. PubMed ID: 23531616
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
7. An acquired hypocalciuric hypercalcemia autoantibody induces allosteric transition among active human Ca-sensing receptor conformations.
Makita N; Sato J; Manaka K; Shoji Y; Oishi A; Hashimoto M; Fujita T; Iiri T
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5443-8. PubMed ID: 17372216
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological characteristics of drugs targeted on calcium-sensing receptor.-properties of cinacalcet hydrochloride as allosteric modulator].
Nagano N; Tsutsui T
Clin Calcium; 2016 Jun; 26(6):839-50. PubMed ID: 27230839
[TBL] [Abstract][Full Text] [Related]
9. [Calcimimetics--a new treatment for hyperparathyroidism?].
Piecha G; Chudek J; Wiecek A
Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961
[TBL] [Abstract][Full Text] [Related]
10. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
11. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action.
Hénaut L; Boudot C; Massy ZA; Lopez-Fernandez I; Dupont S; Mary A; Drüeke TB; Kamel S; Brazier M; Mentaverri R
Cardiovasc Res; 2014 Feb; 101(2):256-65. PubMed ID: 24217682
[TBL] [Abstract][Full Text] [Related]
12. Calcimimetic R-568 and its enantiomer S-568 increase nitric oxide release in human endothelial cells.
Bonomini M; Giardinelli A; Morabito C; Di Silvestre S; Di Cesare M; Di Pietro N; Sirolli V; Formoso G; Amoroso L; Mariggiò MA; Pandolfi A
PLoS One; 2012; 7(1):e30682. PubMed ID: 22295103
[TBL] [Abstract][Full Text] [Related]
13. Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors.
Rus R; Haag C; Bumke-Vogt C; Bähr V; Mayr B; Möhlig M; Schulze E; Frank-Raue K; Raue F; Schöfl C
J Clin Endocrinol Metab; 2008 Dec; 93(12):4797-803. PubMed ID: 18796518
[TBL] [Abstract][Full Text] [Related]
14. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
15. Calcium-Sensing Receptor Internalization Is
Mos I; Jacobsen SE; Foster SR; Bräuner-Osborne H
Mol Pharmacol; 2019 Oct; 96(4):463-474. PubMed ID: 31399503
[TBL] [Abstract][Full Text] [Related]
16. Calcium sensing receptor activators: calcimimetics.
Harrington PE; Fotsch C
Curr Med Chem; 2007; 14(28):3027-34. PubMed ID: 18220738
[TBL] [Abstract][Full Text] [Related]
17. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
Nemeth EF; Shoback D
Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
[TBL] [Abstract][Full Text] [Related]
18. Identification of Global and Ligand-Specific Calcium Sensing Receptor Activation Mechanisms.
Keller AN; Kufareva I; Josephs TM; Diao J; Mai VT; Conigrave AD; Christopoulos A; Gregory KJ; Leach K
Mol Pharmacol; 2018 Jun; 93(6):619-630. PubMed ID: 29636377
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
20. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor.
Lu JY; Yang Y; Gnacadja G; Christopoulos A; Reagan JD
J Pharmacol Exp Ther; 2009 Dec; 331(3):775-86. PubMed ID: 19759318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
